Pharming Group (NASDAQ:PHAR) Rating Increased to Strong-Buy at Zacks Research

Pharming Group (NASDAQ:PHAR) was upgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a report issued on Thursday,Zacks.com reports.

Separately, Weiss Ratings raised shares of Pharming Group from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Saturday, October 25th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $30.00.

Pharming Group Stock Up 5.0%

NASDAQ PHAR opened at $15.43 on Thursday. The company’s 50 day simple moving average is $14.30 and its 200 day simple moving average is $12.01. The company has a debt-to-equity ratio of 0.38, a current ratio of 2.79 and a quick ratio of 2.07. The company has a market capitalization of $1.06 billion, a P/E ratio of -1,541.46 and a beta of 0.03. Pharming Group has a 12 month low of $7.31 and a 12 month high of $17.08.

Pharming Group (NASDAQ:PHAR) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.05 by $0.05. Pharming Group had a return on equity of 0.48% and a net margin of 0.30%.The firm had revenue of $97.30 million during the quarter, compared to the consensus estimate of $98.22 million. Pharming Group has set its FY 2025 guidance at EPS. Equities research analysts expect that Pharming Group will post -0.2 earnings per share for the current fiscal year.

Institutional Trading of Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its stake in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) by 8.6% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 52,147 shares of the company’s stock after purchasing an additional 4,150 shares during the quarter. Silverberg Bernstein Capital Management LLC owned 0.08% of Pharming Group worth $557,000 as of its most recent SEC filing. Institutional investors and hedge funds own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.